WO1993002105A1 - Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments____________________ - Google Patents

Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments____________________ Download PDF

Info

Publication number
WO1993002105A1
WO1993002105A1 PCT/US1992/006043 US9206043W WO9302105A1 WO 1993002105 A1 WO1993002105 A1 WO 1993002105A1 US 9206043 W US9206043 W US 9206043W WO 9302105 A1 WO9302105 A1 WO 9302105A1
Authority
WO
WIPO (PCT)
Prior art keywords
fab
agent
trifunctional compound
compound
moiety
Prior art date
Application number
PCT/US1992/006043
Other languages
English (en)
Inventor
Lana S. Grauer
Clarence N. Ahlem
Original Assignee
Hybritech Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Incorporated filed Critical Hybritech Incorporated
Priority to EP92916746A priority Critical patent/EP0596011A1/fr
Publication of WO1993002105A1 publication Critical patent/WO1993002105A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

L'invention concerne des composés trifonctionnels ayant une réactivité spécifique avec les P-glycoprotéines associés à des cellules tumorales résistant à plusieurs médicaments. Ces composés peuvent être aussi bien spécifiques de manière facultative pour des agents diagnostiques et/ou thérapeutiques et entrent de ce fait dans la composition de produits pharmaceutiques. L'invention comporte également des méthodes de dépistage et de traitement des patients atteints de tumeurs exprimant des P-glycoprotéines associés à des cellules résistant à plusieurs médicaments.
PCT/US1992/006043 1991-07-19 1992-07-17 Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments____________________ WO1993002105A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP92916746A EP0596011A1 (fr) 1991-07-19 1992-07-17 Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments--------------------

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73296991A 1991-07-19 1991-07-19
US732,969 1991-07-19

Publications (1)

Publication Number Publication Date
WO1993002105A1 true WO1993002105A1 (fr) 1993-02-04

Family

ID=24945654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/006043 WO1993002105A1 (fr) 1991-07-19 1992-07-17 Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments____________________

Country Status (4)

Country Link
EP (1) EP0596011A1 (fr)
AU (1) AU2400692A (fr)
CA (1) CA2113578A1 (fr)
WO (1) WO1993002105A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569141A2 (fr) * 1992-04-14 1993-11-10 Hybritech Incorporated Inhibition de la croissance des tumeurs multirésistantes aux médicaments à l'aide d'anticorps
US5342926A (en) * 1993-06-08 1994-08-30 The Regents Of The University Of California Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
WO1996004313A1 (fr) * 1994-08-05 1996-02-15 Immunomedics, Inc. Immunoconjugues polyspecifiques et composites d'anticorps permettant le ciblage du phenotype multipharmacoresistant
WO1996025956A2 (fr) * 1995-02-21 1996-08-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Conjugue pour le dosage individuel de medicaments
WO1997008205A1 (fr) * 1995-08-25 1997-03-06 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo
WO2000002050A1 (fr) * 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Reactif trifonctionnel pour la conjugaison avec une biomolecule
WO2000014537A2 (fr) * 1998-09-04 2000-03-16 Immunomedics, Inc. Diagnostic de resistance a plusieurs medicaments dans des lesions infectieuses et cancereuses
WO2001023565A1 (fr) * 1999-09-28 2001-04-05 Gentest Corporation P-glycoproteines provenant de macaca fascicularis et utilisations correspondantes
WO2001068089A1 (fr) * 2000-03-17 2001-09-20 Indena S.P.A. Utilisation des derives de condensation de thiocolchicine et de baccatine comme agents antitumoraux
US6855812B2 (en) 2001-03-19 2005-02-15 Becton, Dickinson And Company P-glycoproteins and uses thereof
EP2300501A2 (fr) * 2008-07-23 2011-03-30 Hanmi Holdings Co., Ltd. Complexe de polypeptide comprenant un polymère non-peptidylique ayant trois extrémités fonctionnelles
US8951499B2 (en) 1996-02-08 2015-02-10 University Of Washington Trifunctional reagent for conjugation to a biomolecule

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001407A1 (fr) * 1984-08-31 1986-03-13 Hybritech Incorporated Anticorps monoclonaux contre les chelates metalliques
EP0453082A1 (fr) * 1990-03-09 1991-10-23 Hybritech Incorporated Composés trifonctionnels similaires à des anticorps comme agent diagnostique et thérapeutique combiné

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001407A1 (fr) * 1984-08-31 1986-03-13 Hybritech Incorporated Anticorps monoclonaux contre les chelates metalliques
EP0453082A1 (fr) * 1990-03-09 1991-10-23 Hybritech Incorporated Composés trifonctionnels similaires à des anticorps comme agent diagnostique et thérapeutique combiné

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH vol. 49, no. 12, 15 June 1989, PHILADELPHIA, PA, US pages 3209 - 3214 M. B. MEYERS ET AL. 'CHARACTERIZATION OF MONOCLONAL ANTIBODIES RECOGNIZING A Mr 180,000 P-GLYCOPROTEIN: DIFFERENTIAL EXPRESSION OF THE Mr 180,000 AND Mr 170,000 P-GLYCOPROTEINS IN MULTIDRUG-RESISTANT HUMAN TUMOR CELLS.' cited in the application *
INTERNATIONAL JOURNAL OF CANCER vol. 44, no. 4, 15 October 1989, GENEVA, CH pages 738 - 743 J. VAN DIJK ET AL. 'BISPECIFIC ANTIBODIES REACTIVE WITH THE MULTIDRUG-RESISTANCE-RELATED GLYCOPROTEIN AND CD3 INDUCE LYSIS OF MULTIDRUG-RESISTANT TUMOR CELLS.' cited in the application *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569141A2 (fr) * 1992-04-14 1993-11-10 Hybritech Incorporated Inhibition de la croissance des tumeurs multirésistantes aux médicaments à l'aide d'anticorps
EP0569141A3 (fr) * 1992-04-14 1994-10-26 Hybritech Inc Inhibition de la croissance des tumeurs multirésistantes aux médicaments à l'aide d'anticorps.
US5342926A (en) * 1993-06-08 1994-08-30 The Regents Of The University Of California Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
WO1994028943A1 (fr) * 1993-06-08 1994-12-22 The Regents Of The University Of California Analogues de cytochalasine b utilises comme produits pharmaceutiques marques pour visualiser par imagerie nucleaire le transport du glucose a travers la membrane
US5407658A (en) * 1993-06-08 1995-04-18 The Regents Of The University Of California Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
WO1996004313A1 (fr) * 1994-08-05 1996-02-15 Immunomedics, Inc. Immunoconjugues polyspecifiques et composites d'anticorps permettant le ciblage du phenotype multipharmacoresistant
US5698178A (en) * 1994-08-05 1997-12-16 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US6468530B1 (en) 1994-08-05 2002-10-22 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US7067128B2 (en) 1994-08-05 2006-06-27 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
WO1996025956A2 (fr) * 1995-02-21 1996-08-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Conjugue pour le dosage individuel de medicaments
WO1996025956A3 (fr) * 1995-02-21 1996-12-27 Deutsches Krebsforsch Conjugue pour le dosage individuel de medicaments
US6410695B1 (en) 1995-02-21 2002-06-25 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Individual medicament dosing conjugate
WO1997008205A1 (fr) * 1995-08-25 1997-03-06 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH Anticorps presentant deux specificites ou plus pour l'elimination specifique de cellules in vivo
US8951499B2 (en) 1996-02-08 2015-02-10 University Of Washington Trifunctional reagent for conjugation to a biomolecule
WO2000002051A1 (fr) * 1998-07-07 2000-01-13 Dept. Of Radiation Oncology, University Of Washington Reactif trifonctionnel pour la conjugaison avec une biomolecule
WO2000002050A1 (fr) * 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Reactif trifonctionnel pour la conjugaison avec une biomolecule
WO2000014537A3 (fr) * 1998-09-04 2000-07-20 Immunomedics Inc Diagnostic de resistance a plusieurs medicaments dans des lesions infectieuses et cancereuses
WO2000014537A2 (fr) * 1998-09-04 2000-03-16 Immunomedics, Inc. Diagnostic de resistance a plusieurs medicaments dans des lesions infectieuses et cancereuses
US6617450B1 (en) 1999-09-28 2003-09-09 Becton Dickinson And Company P-glycoproteins and uses thereof
WO2001023565A1 (fr) * 1999-09-28 2001-04-05 Gentest Corporation P-glycoproteines provenant de macaca fascicularis et utilisations correspondantes
US6683109B2 (en) * 2000-03-17 2004-01-27 Indena S.P.A. Condensation derivatives of thiocolchicine and baccatin as antitumor agents
WO2001068089A1 (fr) * 2000-03-17 2001-09-20 Indena S.P.A. Utilisation des derives de condensation de thiocolchicine et de baccatine comme agents antitumoraux
US6855812B2 (en) 2001-03-19 2005-02-15 Becton, Dickinson And Company P-glycoproteins and uses thereof
JP2011529046A (ja) * 2008-07-23 2011-12-01 ハンミ ホールディングス カンパニー リミテッド 三末端官能基を有する非ペプチド性重合体を用いた生理活性ポリペプチド薬物結合体
EP2300501A4 (fr) * 2008-07-23 2012-02-01 Hanmi Holdings Co Ltd Complexe de polypeptide comprenant un polymère non-peptidylique ayant trois extrémités fonctionnelles
AU2009274738B2 (en) * 2008-07-23 2012-12-13 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
EP2300501A2 (fr) * 2008-07-23 2011-03-30 Hanmi Holdings Co., Ltd. Complexe de polypeptide comprenant un polymère non-peptidylique ayant trois extrémités fonctionnelles
US9636420B2 (en) 2008-07-23 2017-05-02 Hanmi Science Co., Ltd. Polypeptide complex comprising non-peptidyl polymer having three functional ends
US10071171B2 (en) 2008-07-23 2018-09-11 Hanmi Science Co., Ltd. Polypeptide complex comprising non-peptidyl polymer having three functional ends
US11040110B2 (en) 2008-07-23 2021-06-22 Hanmi Science Co., Ltd. Polypeptide complex comprising non-peptidyl polymer having three functional ends

Also Published As

Publication number Publication date
CA2113578A1 (fr) 1993-02-04
AU2400692A (en) 1993-02-23
EP0596011A1 (fr) 1994-05-11

Similar Documents

Publication Publication Date Title
US4863713A (en) Method and system for administering therapeutic and diagnostic agents
EP0550663B1 (fr) Anticorps modifies a temps de clairance regule
AU613318B2 (en) Affinity enhancement system
US5922847A (en) Methods of purifying hematopoietic cells using an antibody to a stem cell factor receptor
KR0135632B1 (ko) 감염성 및 염증성 병변 표적용 항-백혈구 결합체 및 이를 함유하는 제제 및 키트
CA2031129C (fr) Anticorps chimere pour la detection et le traitement de lesions infectieuses et inflammatoires
JP2968474B2 (ja) 抗−ヒト乳癌モノクローナル抗体を産生するハイブリドーマ
US5034223A (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
USRE38008E1 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
PT94565B (pt) Novos anticorpos reactivos com carcinomas humanos
JPH04502702A (ja) ヒト癌に対する新規なモノクローナル抗体
WO1993002105A1 (fr) Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments____________________
AU616161B2 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
CA2066031C (fr) Methodes de reduction de la retention non recherchee d'immunoconjugues et metabolites obtenus
Vacca et al. Imaging of human leukemic T‐Cell Xenografts in nude mice by radiolabeled monoclonal antibodies and F (ab') 2 fragments
US5250297A (en) Tumor-associated antigen, antibodies, compositions and uses therefor
US6440733B1 (en) Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
JPH01502195A (ja) 細胞毒性結合物の増強法
Li et al. Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity
EP0356397A2 (fr) Anticorps monoclonaux et antigène de surface cellulaire de carcinome pulmonaire
EP0424107A1 (fr) Un antigène nouveau associé aux tumeurs
de Jonge et al. Radioimmunodetection of human small cell lung carcinoma xenografts in the nude rat using 111in-labelled monoclonal antibody MOC-31
KITAMURA et al. Binding, internalization and the cytotoxicity of monoclonal antibody A7-neocarzinostatin conjugates (A7-NCS) in target cells
Endo et al. Tumor imaging by monoclonal antibodies labeled with radioactive metal ions
PL168711B1 (pl) Sposób wytwarzania rekombinantu nowego przeciwciala obejmujacego region wiazaniantygenu mysiego przeciwciala monoklonalnego BR 96 PL

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2113578

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1992916746

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992916746

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1992916746

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992916746

Country of ref document: EP